Inhibition of local calcergy by topical application of calciphylactic challengers

Selye, Hans; Somogyi, Árpád; Mécs, I

doi:10.1007/bf02279195

Cited by 10 publications

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These agents generally induced an inflammatory reaction that days later resulted in calcification. Such a ''sensitization'' stage followed by a ''challenge'' stage was thought to be the steps of this visceral organ calcification (9)(10)(11)(12)(13). It was postulated that such an ''anaphylactic'' inflammation followed by deposition of calcium was a process that occurred in dialysis patients.…”

Section: Origin Of the Term Calciphylaxismentioning

confidence: 99%

Calciphylaxis: Emerging Concepts in Prevention, Diagnosis, and Treatment

Wilmer

Magro

2002

Seminars in Dialysis

265

295

View full text Add to dashboard Cite

Calciphylaxis is a small vessel vasculopathy involving mural calcification with intimal proliferation, fibrosis, and thrombosis. This syndrome occurs predominantly in individuals with renal failure and results in ischemia and necrosis of skin, subcutaneous fat, visceral organs, and skeletal muscle. The syndrome causes significant morbidity in the form of infection, organ failure, and pain. Mortality rates are high. In individuals with renal failure, risk factors for the development of calciphylaxis include female sex, Caucasian race, obesity, and diabetes mellitus. Many cases occur within the first year of dialysis treatment. Several recent reports demonstrate that prolonged hyperphosphatemia and/or elevated calcium x phosphorus products are associated with the syndrome. Protein malnutrition increases the likelihood of calciphylaxis, as does warfarin use and hypercoagulable states, such as protein C and/or protein S deficiency. Recent advances in diagnostic tools and therapeutic strategies have helped in the management of patients with calciphylaxis.

show abstract

Section: Origin Of the Term Calciphylaxismentioning

confidence: 99%

Calciphylaxis: Emerging Concepts in Prevention, Diagnosis, and Treatment

Wilmer

Magro

2002

Seminars in Dialysis

265

295

View full text Add to dashboard Cite

show abstract

Interleukin-1 receptor antagonist inhibits calcium accumulation in in vivo chronic granuloma induced by potassium permanganate

et al. 1993

View full text Add to dashboard Cite

Interleukin-1 (IL-1) is a monokine that exerts multiple biological activity, including immunity and inflammation. Moreover, IL-1 is involved in Ca2+ release causing hypercalcemia and bone resorption. Recently, a 22 kDa natural inhibitor to IL-1 called interleukin-1 receptor antagonist (IL-1ra) has been described in human fluids, which specifically binds IL-1 alpha or IL-1 beta receptors. In this study, we found that experimental granuloma induced by subcutaneous injections (0.2 ml) of potassium permanganate (KMnO4) 1:40 saturated crystal solution, after 7 days was strongly inhibited in size, weight and calcium content (measured as dry ash weight by incineration of granuloma tissue) compared with untreated controls, in mice treated intraperitoneally with IL-1ra (20 micrograms/bolus) given twice; the first at the same time of the induction of the granuloma and the second 24 hours later. In addition, leukotriene B4 and prostaglandin E2 were also inhibited in fresh granuloma of mice treated with IL-1ra. Taken together, these findings conclude for the first time, that the accumulation of calcium in chronic inflammatory states is strongly inhibited by IL-1ra, which decreases tissue calcergy and can potentially be useful for the treatment of calcium-related inflammatory diseases and malignancy-associated hypercalcemia.

show abstract

4-Deoxypyridoxine inhibits chronic granuloma formation induced by potassium permanganatein vivo

et al. 1994

View full text Add to dashboard Cite

4-Deoxypyridoxine (4-DPD) is a potent antagonist of Vitamin B6 coenzyme which inhibits IL-1, lymphocyte proliferation and has demonstrated that tolerance to skin grafts can be induced by administering splenic cells to pyridoxine-deficient mice. Chronic inflammation induced by dorsal injections of 200 microliters of a 1:40 saturated crystal solution of potassium permanganate (KMnO4) in mice treated or untreated with 4-DPD (400 micrograms/dose), has been investigated. After 7 days all mice developed a subcutaneous granulomatous tissue indicative of a chronic inflammatory response, at the site of injection. KMnO4-treated mice injected intraperitoneally with 4-DPD (400 micrograms/dose) on 5 consecutive days (the first at the same time of induction of the granuloma) show a significant decrease in size and weight of granuloma when compared to mice not treated with 4-DPD (Controls). In addition, in all mice treated with 4-DPD there was a strong inhibition of TNF alpha in serum (P < 0.01) and in supernatant fluids (P < 0.05) from minced granuloma, while IL-6 was inhibited in the supernatant fluids (P < 0.05) of minced granulomas but was not detected in the serum of treated and untreated mice. In this study we show for the first time the antiinflammatory effect of 4-DPD on chronic inflammation and the inhibitory effect of TNF and IL-6 generation in supernatant fluids from minced granulomas.

show abstract

Inhibition of local calcergy by topical application of calciphylactic challengers

Cited by 10 publications

References 6 publications

Calciphylaxis: Emerging Concepts in Prevention, Diagnosis, and Treatment

Calciphylaxis: Emerging Concepts in Prevention, Diagnosis, and Treatment

Interleukin-1 receptor antagonist inhibits calcium accumulation in in vivo chronic granuloma induced by potassium permanganate

4-Deoxypyridoxine inhibits chronic granuloma formation induced by potassium permanganatein vivo

Contact Info

Product

Resources

About